Novartis Strengthens Heart-Care Portfolio with Pfizer Brand Buyout
What Happened
Novartis India has acquired the Minipress and Minipres trademarks and related IP rights from Pfizer for ₹1,250 crore. The brands, led by Minipress XL (prazosin), are used to treat high blood pressure and urinary symptoms associated with enlarged prostate (BPH). Pfizer has simultaneously discontinued the marketing and sale of Minipress XL in India following a global manufacturing decision.
Key Takeaways
The acquisition strengthens Novartis India's cardiovascular portfolio with an established brand that generated ₹228.6 crore in revenue in the year ended July 2026. The deal also marks Pfizer’s exit from the product in India, creating an opportunity for Novartis to expand its presence in the hypertension market.